Sun Pharmaceutical Industries Limited (SUNPHARMA) — Financial Results | 22 May 2026 (2 announcements)

Sun Pharmaceutical Industries Limited reported audited standalone financial results for FY26 ending March 31, 2026, with total revenue of ₹350,128 million and net profit of ₹118,093 million, reflecting a 13.6% YoY sales increase in Q4FY26 and 26.2% net profit growth. The company recommended a final dividend of ₹5 per share and disclosed exceptional charges of ₹17,112 million related to litigation settlements. Tax benefits from new labor code provisions and adoption of the concessional tax regime under Section 115BAA contributed to profitability. Total assets stood at ₹309,000 million, with cash and cash equivalents at ₹65,032 million. The auditor issued an unmodified opinion on consolidated financial statements.

Sun Pharmaceutical announced that the audio recording of its FY26 Q4 earnings call held on 22 May 2026 is now available on its website via a direct link, providing investors access to the full discussion of results and management commentary.